Compare Brown-Forman Corporation Class B (BF.B) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs Zoetis Inc — how do they compare? Brown-Forman Corporation Class B trades at $27.67, while Zoetis Inc trades at $72.56 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Brown-Forman Corporation Class B pays none, and Brown-Forman Corporation Class B is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| BF.B | ZTS | |
|---|---|---|
Sector | Consumer Staples | Health |
52-Week High | $31.26 | $156.76 |
52-Week Low | $22.80 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BF.B trades at $28.19, down 1.16% for the day, with technical indicators showing a bullish trend supported by moving averages. The stock has demonstrated strong earnings performance, beating expectations in three of the last four quarters. Analyst sentiment is mixed with a 25% buy rating amid limited recent news coverage.
The outlook remains cautiously optimistic given recent earnings strength, though the divided analyst consensus and lack of current financial metrics present valuation challenges. Key risks include execution consistency and market volatility, while institutional positioning will be critical for sustained momentum.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
